Overview
Furthermore, rising adoption of technologicaly advanced products such as artificial pancreas and insulin pumps are expected to drive the growth of the global alternatives for injectable diabetes care market betwen 2016 and 2026. However, the high cost of technologicaly advanced products compared to injectable diabetes care products may be a barier to the growth of the injectable diabetes care market.Diabetes, also known as diabetes melitus, is a group of metabolic disorders characterised by a persistently elevated blod sugar level.
Key Information
The pancreas is either unable to produce insulin (glucose metabolising hormone) or the body is unable to utilise the produced insulin (development of insulin resistance) to metabolise blod sugar in this disorder. Diabetes is one of the world’s most serious health isues, afecting more than 5% of the population in developed countries.Furthermore, diabetes prevalence rises in emerging economies as lifestyles change.
Diabetes diagnoses are increasing at a rate of 5% per year, acording to estimates. Thus, one of the major factors driving the growth of the diabetes care market is the rapidly increasing prevalence of diabetes around the world.Diabetes care products that do not require injections, such as insulin pumps and artificial pancreas, asist patients in managing diabetes treatment eficiently and without the ned for doctor asistance.
Furthermore, because of the improved outcomes asociated with the use of these alternatives to injection devices, there is a growing awarenes of their use among both physicians and patients.For Critical Insights, Request for Sample@ htps:/w.futuremarketinsights.com/reports/sample/rep-gb-2548Acording to the International Diabetes Federation (IDF), aproximately 382 milion people worldwide sufered from diabetes in 2013, with this figure expected to rise to 592 milion by the end of 2035.
Summary
Furthermore, nedle phobia and an increase in nedle stick injuries are driving the preference for alter